A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
2期
进行中（已停止招募）
NCT02623972
| 适应症 | Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Dana-Farber Cancer Institute |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 22 人 |
|---|
| 干预（药物） | Eribulin, Adriamycin, Cyclophosphamide |
|---|
| 开始日期 | 2016年2月26日 |
|---|
| 完成日期 | 2021年5月 |
|---|
| 结果公布日 | 2022年12月28日 |
|---|
摘要
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Pathologic Complete Response Rate
Assessed after preoperative therapy with either 4 cycles of eribulin mesylate (3 wks) followed by 4 cycles of doxorubicin/cyclophosphamide (2 wks) or after 4 cycles of AC(2 wks) followed by 4 cycles of eribulin(3 wks). As such up to 20 weeks. · percentage of participants
| Arm A: Eribulin Followed by AC | 6.25 percentage of participants |
|---|
| Arm B: AC Followed by Eribulin | 0 percentage of participants |
|---|
| Pathelogic Complete Response Rate | 30 |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。